Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide

PHASE3CompletedINTERVENTIONAL
Enrollment

318

Participants

Timeline

Start Date

June 30, 1999

Primary Completion Date

February 28, 2005

Study Completion Date

March 31, 2008

Conditions
Anaplastic AstrocytomaOligodendrogliomaOligoastrocytoma
Interventions
DRUG

Temozolomide

200 mg/m2 body surface on days 1-5 every 28 days for 8 cycles; and again for another 4 cycles at primary progression

RADIATION

Focal radiotherapy

54-60 Gy in 28-30 fractions over 6-7 weeks

Trial Locations (12)

69120

University of Heidelberg, Heidelberg

72076

Neurology and Radiotherapy, Tübingen

Unknown

Klinikum Aschaffenburg, Aschaffenburg

Nervenklinik, Bamberg

Charite, Berlin

Neurosurgery, Düsseldorf

Radiotherapy, Erlangen

Neurology, Essen

Neurosurgery, Frankfurt

Neurosurgery, Kiel

Neurosurgery, Mainz

County District Hospital, Regensburg

All Listed Sponsors
collaborator

University Hospital Tuebingen

OTHER

collaborator

Heinrich-Heine University, Duesseldorf

OTHER

collaborator

Heidelberg University

OTHER

collaborator

Charite University, Berlin, Germany

OTHER

collaborator

University Hospital, Essen

OTHER

collaborator

University of Leipzig

OTHER

collaborator

University Hospital, Bonn

OTHER

collaborator

German Cancer Research Center

OTHER

collaborator

University of Zurich

OTHER

lead

Neuro-Oncology Working Group of the German Cancer Society

NETWORK

NCT00717210 - Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide | Biotech Hunter | Biotech Hunter